Resolve Biosciences: Frank Zhong
Spatial biology firm Resolve Biosciences has appointed Frank Zhong as chief technology officer. He will report to CEO Jason Gammack and will oversee product development and advanced research initiatives.
Zhong has held leadership roles at BGI, where he was CEO of EGI, CTO of BGI Research USA, and VP of advanced research at Complete Genomics. He also was associate director of technology development at Illumina, where he helped develop the iSeq, and worked on optical systems for Pacific Biosciences. Zhong holds a doctorate in applied physics and a masters' degree in electrical engineering from the University of Michigan.
Epic Sciences: Jason Christiansen, Mark Aguillard, Amara Siva
Epic Sciences has appointed Jason Christiansen as chief technology officer, Mark Aguillard as VP and general manager of the oncology business unit, and Amara Siva as VP of laboratory operations.
Christiansen has 20 years of experience developing new technologies for research, clinical diagnostics, and new targeted therapy companion diagnostics. He has held executive positions at companies including Roche's sequencing solutions business, Boundless Bio, Ignyta, Genoptix, and HistoRx.
Aguillard previously led commercialization efforts at Myriad Genetics, Binx Health, OmniSeq, and Eli Lilly. He will drive Epic's commercial growth in the clinical oncology space.
Siva has more than 20 years of experience in the molecular diagnostics space and was in laboratory research and operations management at Pathnostics; Millennium Health; Genoptix (now part of NeoGenomics); Gen-Probe (now part of Hologic); and Alexion.
National Institutes of Health: Geoffrey Ginsburg
Geoffrey Ginsburg has been selected as chief medical and scientific officer of the National Institutes of Health's All of Us Research Program. He will lead the program's division of medical and scientific research. Ginsburg is the founding director of the Center for Applied Genomics & Precision Medicine at Duke University School of Medicine. He is also a professor of medicine, pathology, and biostatistics and bioinformatics at Duke University School of Medicine, a professor of biomedical engineering at the Pratt School of Engineering, and a professor at the School of Nursing. Prior to that, he held leadership positions at Millennium Pharmaceuticals and was a faculty member at Harvard Medical School, and he was the director of preventive cardiology at Beth Israel Hospital.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.